University of Rochester

The State University of New York

Abbvie Biotechnology Ltd

Christopher T Ritchlin

Edward M Schwarz

Kofi A Mensah

Sally A Haas-Smith

Yahui Grace Chiu

Lorne M Golub

Rebecca S Hoffman

Robert A Greenwald

Hsi-Ming Lee

John R Medich

Robert L Wong

Renee J Perdok

Phillip Mease

Susan A Moak

Eric H Sasso

Sally Haas-Smith

Provided herein are antibodies that specifically bind an epitope of DC-STAMP. Specifically, provided herein are monoclonal antibodies that bind an epitope of DC-STAMP, wherein the epitope comprises the amino acid sequence Glu-Val-His-Leu-Lys-Leu-His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:1). Optionally, the epitope comprises the amino acid sequence His-Gly-Glu-Lys-Gln-Gly-Thr-Gln (SEQ ID NO:2). Optionally, the epitope comprises the amino acid sequence Lys-Gln-Gly-Thr-Gln (SEQ ID NO:3).

DC-STAMP antibodies

The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNF&#x3b1; inhibitor, such as a human TNF&#x3b1; antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNF&#x3b1; inhibitor for treatment of psoriatic arthritis in a subject.

Uses and compositions for treatment of psoriatic arthritis

Disclosed are compositions and methods related to joint inflammation diseases. Disclosed is the relationship between osteoclasts and inflammatory joint diseases and osteoclast precursor cells.

Methods and compositions related to joint inflammation diseases

The invention is a method of enhancing endogenous interleukin-10 production in mammalian cells and tissues, which includes administering an effective amount of a tetracycline derivative. The method also includes enhancing interleukin-10 production by administering an effective amount of the tetracycline derivative to a mammal. Preferred tetracycline compounds are tetracycline compounds which have been modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by excessive IL-1 and TNF .alpha. production.

Method of using tetracycline compounds to enhance interleukin-10

Growing community of inventors

Canandaigua, NY, United States of America

Christopher T Ritchlin